Gilead Science has acquired a 49.9% stake in Tizona Therapeutics for $300m with the option to buy the remainder for $1.23 bn. This comes as Tizona's cancer therapy drug has been cleared by the U.S. Food and Drug Administration.
“Gilead’s support will enable Tizona to accelerate and broaden our TTX-080 clinical program while also enabling us to rapidly advance our rich, first-in-class preclinical portfolio and target validation efforts,”
Scott Clarke, Chief Executive Officer, Tizona